Free Trial

BioHarvest Sciences (BHST) Competitors

BioHarvest Sciences logo
$5.33 +0.01 (+0.19%)
As of 03/10/2025 03:48 PM Eastern

BHST vs. ESPR, MBX, TERN, ALDX, BNTC, ATAI, SEPN, ANNX, IMMP, and DMAC

Should you be buying BioHarvest Sciences stock or one of its competitors? The main competitors of BioHarvest Sciences include Esperion Therapeutics (ESPR), MBX Biosciences (MBX), Terns Pharmaceuticals (TERN), Aldeyra Therapeutics (ALDX), Benitec Biopharma (BNTC), Atai Life Sciences (ATAI), Septerna (SEPN), Annexon (ANNX), Immutep (IMMP), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical preparations" industry.

BioHarvest Sciences vs.

BioHarvest Sciences (NASDAQ:BHST) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.

Esperion Therapeutics received 624 more outperform votes than BioHarvest Sciences when rated by MarketBeat users. However, 100.00% of users gave BioHarvest Sciences an outperform vote while only 70.18% of users gave Esperion Therapeutics an outperform vote.

CompanyUnderperformOutperform
BioHarvest SciencesOutperform Votes
2
100.00%
Underperform Votes
No Votes
Esperion TherapeuticsOutperform Votes
626
70.18%
Underperform Votes
266
29.82%

BioHarvest Sciences currently has a consensus price target of $13.00, indicating a potential upside of 143.90%. Esperion Therapeutics has a consensus price target of $6.75, indicating a potential upside of 327.22%. Given Esperion Therapeutics' higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than BioHarvest Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioHarvest Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Esperion Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

BioHarvest Sciences has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

BioHarvest Sciences has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioHarvest Sciences$22.43M3.90-$12.56M-$1.25-4.26
Esperion Therapeutics$332.31M0.94-$209.25M-$0.25-6.32

Esperion Therapeutics has a net margin of -29.37% compared to BioHarvest Sciences' net margin of -76.65%.

Company Net Margins Return on Equity Return on Assets
BioHarvest Sciences-76.65% N/A -85.16%
Esperion Therapeutics -29.37%N/A -10.77%

In the previous week, Esperion Therapeutics had 19 more articles in the media than BioHarvest Sciences. MarketBeat recorded 20 mentions for Esperion Therapeutics and 1 mentions for BioHarvest Sciences. Esperion Therapeutics' average media sentiment score of 0.62 beat BioHarvest Sciences' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioHarvest Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Esperion Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

47.4% of Esperion Therapeutics shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Esperion Therapeutics beats BioHarvest Sciences on 12 of the 17 factors compared between the two stocks.

Remove Ads
Get BioHarvest Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHST and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHST vs. The Competition

MetricBioHarvest SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$87.55M$7.11B$5.72B$8.00B
Dividend YieldN/A2.72%4.89%4.03%
P/E Ratio-4.276.3024.9018.90
Price / Sales3.90219.97401.45115.03
Price / CashN/A65.6738.0534.62
Price / Book-4.946.387.274.15
Net Income-$12.56M$140.25M$3.19B$246.75M
7 Day Performance5.96%0.08%-0.85%-2.17%
1 Month Performance-10.42%-8.45%-6.83%-9.12%
1 Year PerformanceN/A-12.30%11.07%-0.27%

BioHarvest Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BHST
BioHarvest Sciences
N/A$5.33
+0.2%
$13.00
+143.9%
N/A$87.55M$22.43M-4.27N/AGap Down
High Trading Volume
ESPR
Esperion Therapeutics
4.4422 of 5 stars
$1.70
+2.4%
$6.75
+297.1%
-27.9%$334.96M$295.45M-2.66200Analyst Revision
MBX
MBX Biosciences
2.2036 of 5 stars
$9.60
-2.2%
$37.25
+288.0%
N/A$320.80MN/A0.0036Lockup Expiration
TERN
Terns Pharmaceuticals
4.3765 of 5 stars
$3.69
flat
$18.30
+395.9%
-58.6%$313.43MN/A-3.1340Upcoming Earnings
ALDX
Aldeyra Therapeutics
1.6327 of 5 stars
$5.11
-19.4%
$10.00
+95.7%
+82.9%$304.30MN/A0.0015Earnings Report
High Trading Volume
BNTC
Benitec Biopharma
2.5513 of 5 stars
$12.71
+11.4%
$24.43
+92.2%
+150.9%$298.06M$80,000.00-8.4220Positive News
ATAI
Atai Life Sciences
3.2889 of 5 stars
$1.72
+4.2%
$9.00
+423.3%
-32.9%$288.62M$331,000.00-2.1280
SEPN
Septerna
2.3354 of 5 stars
$6.47
+11.6%
$34.00
+425.5%
N/A$287.29M$981,000.000.00N/AUpcoming Earnings
ANNX
Annexon
2.0218 of 5 stars
$2.64
+5.6%
$15.80
+498.5%
-47.5%$281.40MN/A-2.5160Earnings Report
Analyst Revision
IMMP
Immutep
1.1105 of 5 stars
$1.93
+1.6%
$8.50
+340.4%
-36.4%$280.93M$5.14M0.002,021News Coverage
Positive News
DMAC
DiaMedica Therapeutics
1.7573 of 5 stars
$6.53
+2.4%
$7.00
+7.2%
+78.8%$279.23MN/A-11.6620
Remove Ads

Related Companies and Tools


This page (NASDAQ:BHST) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners